Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY22 Earnings Presentation
18 slides from Eris Lifesciences's earnings presentation, Jan 28, 2022
Slide 1: Stock exchange cover letter: Investor Presentation
Date: 28th January, 2022 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the req
Slide 2: Q3 FY22 and 9M FY22 Investor Presentation
Q3 FY 22 and 9M FY 22 INVESTOR PRESENTATION 28th January 2022 1
Slide 3: Financial Highlights – Q3 FY22 and 9M FY22
FINANCIAL HIGHLIGHTS – Q3 FY 22 and 9M FY 22 Q3 FY 22 9M FY 22 INR mn INR mn INR mn INR mn 3,322 1,217 10,411 3,881 7.0% 13.5% 11.5% 15.5% Op Revenue yoy growth EBITDA yoy growth Op Revenue yoy growth EBITDA yoy growth INR mn INR mn 1,008 3,258 11.8% 13.6% PAT yoy growth PAT yoy growth • Grew by 16.
Slide 4: Eris Has Grown at Twice the Market Rate from Pre-Covid Levels
ERIS HAS GROWN AT TWICE THE MARKET RATE FROM PRE-COVID LEVELS Eris has outperformed the IPM by 710 bps since 19.3% pre-Covid times 13.9% 13.1% 11.8% 11.7% 11.5% 10.5% 9.9% 8.7% 8.5% 6.8% IPM exl. Covid IPCA ERIS LS MANKIND TORRENT INTAS MACLEODS SUN MICRO ARISTO EMC URE molecules % Acute Therapy con
Slide 5: Sustained Outperformance in Core Therapies from Pre-Covid Levels
SUSTAINED OUTPERFORMANCE IN CORE THERAPIES FROM PRE-COVID LEVELS ORAL ANTI-DIABETES : 32% of Eris CARDIOLOGY : 27% of Eris VMN: 20% of Eris 18.3% 12.3% 12.8% over IPM 7.5% over IPM 16.6% 5.1% over IPM 7.2% 9.1% 6.0% IPM Eris IPM Eris IPM Eris CNS: 8% of Eris WOMEN’S HEALTH: 4% of Eris • Eris has gro
Slide 6: Continued Outperformance in Chronic Despite Slowdown in Cardio-Metabolic Market
CONTINUED OUTPERFORMANCE IN CHRONIC DESPITE A SIGNIFICANT SLOWDOWN IN OUR CORE CARDIO-METABOLIC MARKET IN Q2 AS WELL AS Q3 Eris grew at 7.8% in Q3 FY 22 vs. IPM growth of 5.7%; outperformed IPM in Cardio-Metabolic, CNS & Women’s Health therapies IPM Eris Cardio-Metabolic : 59% of Eris VMN : 20% of E
Slide 7: Leveraging the Insulin/GLP1 Opportunity Through a JV with MJ Biopharm
LEVERAGING THE INSULIN/ GLP1 OPPORTUNITY THROUGH A JV WITH MJ BIOPHARM • Leading position in Indian oral anti-diabetes • Proven capabilities in developing advanced biological formulations from preclinical • Strong credibility with Diabetologists/ through to Phase III and regulatory approval Endocrin
Slide 8: Human Insulin Will Be Launched in Feb 2022
HUMAN INSULIN WILL BE LAUNCHED IN FEB 2022 ERIS PEN (FOR INSULIN CARTRIDGE) INSULIN VIAL* * Monocarton image has been depicted 7
Slide 9: Eris Maintains High Prescription Ranking Among Doctor Specialties
ERIS MAINTAINS HIGH PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 3 4 3 DIABETOLOGISTS CARDIOLOGISTS NEUROLOGISTS 4 CONSULTING 5 GASTROENTEROLOGISTS PHYSICIANS Source: SMSRC MAT Oct 2021 * Rank in Represented Market 8
Slide 10: Power Brands Continue to Have Leading Presence in Core Therapies (1/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/2) Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea rank 6 in the ≈4,700 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimepiri
Slide 11: Power Brands Continue to Have Leading Presence in Core Therapies (2/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (2/2) High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ≈3,700 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipin
Slide 12: Eris Continues to Execute on Growth Drivers (1/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (1/2) Expansion of power- • Our business model of building strong and sustainable brands has enabled us to 1 brands’ franchise significantly outperform the market during the pandemic period (Eris CAGR of ~ 14% vs. IPM CAGR of ~ 7%*) when MR-Doctor interact
Slide 13: Eris Continues to Execute on Growth Drivers (2/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (2/2) Expansion of physician • We continue to make good progress in expanding our coverage of Specialists and 3 coverage Consulting Physicians in line with our expectations Therapeutic Diversification • We continue to invest in diversification opportunitie
Slide 14: Q3 FY22 and 9M FY22 - Standalone Income Statement
Q3 FY 22 AND 9M FY22 - STANDALONE INCOME STATEMENT Standalone Q3 FY 22 9M FY 22 INR Millions Q3 FY 22 Q3 FY 21 9M FY 22 9M FY 21 yoy Gr % yoy Gr % Sale of Products 3,002 2,815 6.7% 9,167 8,360 9.7% • Operating Revenue grew by 6.1% yoy in Q3 FY 22 and Other Operating Income 44 56 -21.8% 169 160 5.7%
Slide 15: Q3 FY22 and 9M FY22 - Consolidated Income Statement
Q3 FY 22 AND 9M FY22 - CONSOLIDATED INCOME STATEMENT Consolidated Q3 FY 22 9M FY 22 Q3 FY 22 Q3 FY 21 9M FY 22 9M FY 21 INR Millions yoy Gr % yoy Gr % Branded Formulation Sales Sale of Products 3,281 3,050 7.6% 10,251 9,184 11.6% Q3 FY 22 9M FY 22 Other Operating Income 41 54 -24.1% 160 153 5.0% INR
Slide 16: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Others 31-Dec-21 30-Sep-21 30-Jun-21 FPIs 0.43% Name of Shareholder 13.34% 760* 761* 708* Promoters 52.66% 52.68% 52.69% 1 ChrysCapital (Emerald Investment Limited) 5.50% 5.50% 5.51% 2 UTI Mutual Fund
Slide 17: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 18: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 17